Method of treatment with tradipitant

Abstract

Disclosed herein are methods of treating an individual who is experiencing or is at risk of experiencing an undesirable consequence of opioid use, and of treating an individual who is experiencing oris at risk of experiencing desire for opioid, and uses of an NK1 receptor antagonist Chudepitant in treating the individual.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 682,831, filed June 8, 2018, which is hereby incorporated by reference in its entirety. Background technique [0003] The present application generally relates to the use of NK-1 receptor antagonists. More specifically, the present application relates to the use of the NK-1 antagonist sendipitant in the treatment of individuals who are experiencing or are likely to experience undesired consequences of opioid use. [0004] Trandipitant (2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridyl)-1H-1,2,3-triazole -4-yl]-3-pyridyl](2-chlorophenyl)-methanone or {2-[1-(3,5-bistrifluoromethylbenzyl)-5-pyridin-4-yl- 1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone) and its pharmaceutically acceptable acid addition salts (collectively referred to herein as "Tendipitant") is known to be a highly potent, selective, centrally penet...

AI Technical Summary

Problems solved by technology

Known opioid addiction resulting in an individual's inability to control the urge to use opioids despite undesired consequences, such as negative effects on personal relationships or finances

Images